^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)

    i
    Other names: IDH2, Isocitrate Dehydrogenase (NADP(+)) 2, Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial, Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial, Isocitrate Dehydrogenase [NADP], Mitochondrial, Oxalosuccinate Decarboxylase, NADP(+)-Specific ICDH, ICD-M, IDH, IDP, MNADP-IDH, D2HGA2, IDHM, IDPM
    17h
    Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations (clinicaltrials.gov)
    P2, N=148, Not yet recruiting, Shen yang
    New P2 trial • Head-to-Head • IO biomarker
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1)
    |
    IDH2 mutation • NPM1 mutation
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin
    19h
    Diffuse Intraductal Breast Papillomatosis in a 34-Year-Old Female With Maffucci Syndrome: A Case Report. (PubMed, Case Rep Radiol)
    This case raises the possibility of an association between Maffucci syndrome and recurrent papillary breast lesions. In the absence of molecular confirmation, this relationship remains speculative and should be regarded as hypothesis generating, underscoring the need for further investigation with genetic and immunohistochemical correlation rather than changes to established breast cancer screening guidelines.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 mutation • IDH2 mutation • IDH2 R172
    23h
    Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas (clinicaltrials.gov)
    P1/2, N=33, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH wild-type
    |
    Zynyz (retifanlimab-dlwr)
    2d
    Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors. (PubMed, Leuk Res)
    This selected real-world cohort demonstrates durable responses exceeding published benchmarks and has one of the longest follow-up periods reported for IDHi in AML. A subset of older adults with IDH-mutated AML can achieve highly durable remissions on IDHi without significant toxicity.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 mutation • IDH2 mutation
    |
    Tibsovo (ivosidenib) • Idhifa (enasidenib)
    3d
    A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=15, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2026 --> Dec 2026 | Trial primary completion date: Aug 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • IL18 (Interleukin 18) • CD37 (CD37 Molecule)
    |
    FLT3-ITD mutation • IDH1 mutation • IDH2 mutation
    |
    CD371-YSNVZ-IL18 CAR T cells
    3d
    Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma. (PubMed, Front Cell Dev Biol)
    We observed substantial rewiring of epigenetic cofactor-related MG expression in CCAs. Functional assays validated new targets among EpiGs (e.g., CBX3, CHD4, DEK, SMARCA4, and TRIM28) and MGs (TYMS and IDH2) in CCA.
    Journal
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • TYMS (Thymidylate Synthetase) • KDM5C (Lysine Demethylase 5C) • DNMT1 (DNA methyltransferase 1) • HDAC1 (Histone Deacetylase 1) • CHD4 (Chromodomain Helicase DNA Binding Protein 4) • HDAC3 (Histone Deacetylase 3) • MAT1A (Methionine Adenosyltransferase 1A) • SHMT1 (Serine Hydroxymethyltransferase 1) • SUZ12 (SUZ12 Polycomb Repressive Complex 2 Subunit) • TRIM28 (Tripartite Motif Containing 28) • CBX3 (Chromobox 3)
    3d
    Reductive carboxylation via isocitrate dehydrogenase 1 supports cardiac metabolic adaptation during oncometabolic stress. (PubMed, bioRxiv)
    Lastly, epigenetic analyses of histone marks revealed that IDH1 induces widespread alterations in histone acetylation and tri-methylation. Our results highlight a novel role for IDH1 in cardiac metabolism and transcriptional control of metabolic adaptation to tumor-mediated stress and provide evidence that reductive-citrate formation may induce epigenetic modifications in the heart.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    4d
    Machine learning-guided risk stratification in elderly AML based on genomic, immunophenotypic and therapeutic profiles. (PubMed, BMC Geriatr)
    This model provides a robust and interpretable tool for individualized risk stratification in elderly AML. By integrating genomic, immunophenotypic, and therapeutic variables, it may help optimize treatment decisions and improve outcomes for this vulnerable population. Future efforts should focus on external validation and integration of dynamic biomarkers.
    Journal
    |
    TP53 (Tumor protein P53) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    TP53 mutation • IDH2 mutation
    6d
    Insight into the metabolism of gliomas by MRI and MRS. (PubMed, Biophys Rev)
    Further, multi-center clinical trials and incorporating metabolic endpoints are necessary for adaptive therapy strategies. Together, MRI and MRS provide a comprehensive view of glioma biology that supports precision diagnosis, risk stratification, and individualized treatment planning, thereby advancing the goal of routine clinical adoption of metabolic imaging in neuro-oncology.
    Review • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • TERT (Telomerase Reverse Transcriptase) • ATRX (ATRX Chromatin Remodeler)
    8d
    CLIP2::MET fusion identifies a molecularly distinct glioneuronal tumor. (PubMed, Discov Oncol)
    MET fusions are actionable oncogenic drivers across several cancers, and their detection has therapeutic relevance with approved inhibitors. This case expands the spectrum of MET-driven CNS tumors and suggests that CLIP2::MET fusion may represent a distinct molecular subset of glioneuronal tumors relevant to precision oncology.
    Journal
    |
    BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    BRAF mutation
    9d
    A072301: Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer (clinicaltrials.gov)
    P3, N=408, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Jul 2026
    Enrollment open • Trial initiation date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2)
    |
    CDKN2A deletion • IDH1 R132
    |
    temozolomide • Voranigo (vorasidenib)
    9d
    Posttranscriptional Regulation of Metabolism in Glioblastoma: A Multipathway Review. (PubMed, J Biochem Mol Toxicol)
    We also discuss therapeutic strategies targeting these miRNA-metabolism circuits, including nanoparticle delivery, dietary restriction, and combination therapies that re-sensitize tumors to temozolomide and radiation. Understanding and therapeutically exploiting these networks presents a powerful approach to overcoming GBM's metabolic resilience, thereby opening new avenues for precision oncology.
    Review • Journal
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CREBBP (CREB binding protein) • MIR200B (MicroRNA 200b) • MIR126 (MicroRNA 126) • MIR375 (MicroRNA 375) • MIR183 (MicroRNA 183) • SLC2A1 (Solute Carrier Family 2 Member 1) • XIST (X Inactive Specific Transcript)
    |
    temozolomide